| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA871: Eptinezumab for preventing migraine |
|
Medicine details |
|
| Medicine name | eptinezumab (Vyepti®) |
| Formulation | 100 mg concentrate for solution for infusion |
| Reference number | 3571 |
| Indication | Prophylaxis of migraine in adults who have at least 4 migraine days per month |
| Company | Lundbeck Ltd |
| BNF chapter | Central nervous system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 07/01/2022 |
| NICE guidance | |